Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Parallel-group Study Assessing the Efficacy and Safety of Sarilumab Monotherapy Versus Adalimumab Monotherapy in Patients With Rheumatoid Arthritis

NCT02332590 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT02332590
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02332590 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Parallel-group Study Assessing the Efficacy and Safety of Sarilumab Monotherapy Versus Adalimumab Monotherapy in Patients With Rheumatoid Arthritis
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
January 28, 2015
Completion date
December 29, 2020
Enrollment
369 (actual)
Sites
86

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis